Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov 30;14(11):3437-3439.
doi: 10.21037/tau-2025-630. Epub 2025 Nov 25.

From surgery to systemic therapy: long-term lessons of belzutifan in von Hippel-Lindau disease

Max Schnoll  1   2 , Pooja Ghatalia  1
Affiliations
Editorial

From surgery to systemic therapy: long-term lessons of belzutifan in von Hippel-Lindau disease

Max Schnoll et al. Transl Androl Urol. .
No abstract available

Keywords: Belzutifan; hypoxia-inducible factor 2-alpha (HIF-2α); renal cell carcinoma (RCC); von Hippel-Lindau (VHL).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-630/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol 2015;132:139-56. 10.1016/B978-0-444-62702-5.00010-X - DOI - PMC - PubMed
    1. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 2011;19:617-23. 10.1038/ejhg.2010.175 - DOI - PMC - PubMed
    1. Haase VH. The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des 2009;15:3895-903. 10.2174/138161209789649394 - DOI - PMC - PubMed
    1. Srinivasan R, Iliopoulos O, Beckermann KE, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol 2025;26:571-82. 10.1016/S1470-2045(25)00099-3 - DOI - PMC - PubMed